Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension

NCT ID: NCT02177409

Last Updated: 2014-07-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 431 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1998-04-30

Brief Summary

The primary aim of the trial is the effect of telmisartan versus amlodipine in lowering ambulatory diastolic and/or systolic blood pressures in the last six hours of the dosing interval in patients with mild-to-moderate hypertension as measured by ambulatory blood pressure monitoring (ABPM)

Conditions

Hypertension

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Telmisartan

4-week placebo run-in, 8-week fixed dose period

Group Type: EXPERIMENTAL

Telmisartan

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Amlodipine

4-week placebo run-in, 8-week fixed dose period

Group Type: ACTIVE_COMPARATOR

Amlodipine

Intervention Type: DEVICE

Placebo

Intervention Type: DRUG

Interventions

Telmisartan

Intervention Type: DRUG

Amlodipine

Intervention Type: DEVICE

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Mild-to-moderate hypertension defined as a mean seated diastolic blood pressure (BP) of ≥ 95 mm Hg and ≤ 114 mm Hg, measured by manual cuff sphygmomanometer, on the last visit (Visit 6) of the four-week placebo run-in period (baseline BP)
• Mean seated systolic blood pressure ≥ 140 mm Hg and ≤ 200 mm Hg, measured by manual cuff at Visit 6 (baseline BP)
• A 24-hour mean ABPM measurement of ≥ 130/85 mm Hg evaluated at Visit 7 (baseline ABPM)
• Age 18 or older
• Ability to provide written informed consent

Exclusion Criteria

• Pre-menopausal women (last menstruation ≤ 1 year prior to start of screening):

• who are not surgically sterile (hysterectomy, tubal ligation)
• who are NOT practicing acceptable means of birth control or who do NOT plan to continue using an acceptable method throughout the study
• Any women:

• Who has a positive serum pregnancy test at screening (Visit 1) or baseline (Visit 7)
• Who is nursing
• Hepatic and/or renal dysfunction as defined by the following laboratory parameters

• SGPT (ALT) (serum glutamate pyruvate transaminase) or SGOT (AST) (serum glutamate oxaloacetate transaminase) greater than two times the upper limit of normal
• Serum creatinine > 2.3 mg/dL
• At screening (Visit 1): clinically relevant sodium depletion, hyperkalemia, or hypokalemia
• Known or suspected secondary hypertension
• Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney; post-renal transplant patients, presence of only one functioning kidney
• Congestive heart failure (CHF) (NYHA (New York Heart Association) class CHF III-IV)
• Unstable angina within the past three months
• Stroke within the past six months
• Myocardial infarction or cardiac surgery within the past three months
• PTCA (percutaneous transluminal coronary angioplasty) within the past three months
• History of angioedema
• Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
• Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant stenosis of the aortic or mitral valve
• Administration of digoxin or other digitalis-type drugs
• Patients with insulin-dependent diabetes mellitus whose diabetes has not been stable and controlled for at least the past three months as defined by an HbA1C ≥ 10%
• Known drug or alcohol dependency within the past one year period
• Concomitant administration of medications known to affect blood pressure, except medications allowed by the protocol
• Night shift workers who routinely sleep during the daytime and whose work hours include midnight to 4:00 AM (ante meridian)
• Patients receiving any investigational therapy within one month of signing the informed consent form. Note that patients who have participated in previous MICARDIS (telmisartan) studies may participate in this study provided there has been at least one month between discontinuing the previous study and signing the consent for the present study
• Known hypersensitivity to any component of the formulations
• Any clinical condition which, in the opinion of the investigator would not allow safe completion of the protocol and safe administration of trial medication

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Boehringer Ingelheim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

502.258

Identifier Type: -

Identifier Source: org_study_id